Full Year 2025 Formycon AG Earnings Call Transcript
Key Points
- Formycon AG (XTER:FYB) outperformed its guidance for EBITDA and working capital, demonstrating the resilience and quality of its business model.
- The company achieved multiple key milestones across all four pillars of its Fit for Growth strategy, marking 2025 as a transformational year.
- Formycon AG has started 2026 strong with positive PK results for its FYB206 Keytruda biosimilar and an agreement with Bayer for the launch of its third biosimilar FYB203.
- The company's strategic geographic diversification into high-growth emerging regions is expected to maximize global value and reduce market dependencies.
- Formycon AG's lean development approach, leveraging digital and AI-supported processes, has materially reduced development timelines and costs, enhancing capital efficiency and scalability.
- Revenues for 2025 were below target due to the transformation of revenue structures and delayed milestones.
- The company experienced a temporary pause in the marketing of FYB201 in the US, leading to a significant decline in revenues.
- Formycon AG faced challenges with its year-end reporting timeline due to changes in the financial team and technical adjustments.
- The US market remains a major challenge for FYB202 due to slow opening of the PBM market and competition from the originator.
- Despite a strong fourth quarter in 2025, revenues from the commercialization of FYB202 developed less dynamically than anticipated.
Good afternoon, good morning, and welcome to everyone joining us today. Before we begin, allow me a brief note on timing as this year's publication of our results came later than usual. The transition of our financial system at year-end was a necessary step, but it required additional diligence in close coordination with our auditors to ensure the highest quality and reliability of our financial reporting.
We appreciate, therefore, your patience in this process. Earlier today, we published our full year 2025 results. And before we go into the presentation, let me highlight three key messages upfront. Number one, in a dynamically and for sure, demanding market environment, we clearly outperformed our guidance for EBITDA and working capital, which is underlining the resilience and quality of our business model.
Even though revenues were lower and partly shifted into the new year. Number two, operationally, 2025 was a highly successful and transformational year for Formycon with multiple key milestones
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
